From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“
To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.
I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
- Forums
- ASX - By Stock
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
From the clip:“We are excited to test sozinibercept in large P3...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
43.5¢ |
Change
0.025(6.10%) |
Mkt cap ! $529.3M |
Open | High | Low | Value | Volume |
42.0¢ | 44.0¢ | 42.0¢ | $473.3K | 1.112M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 39542 | 43.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.5¢ | 55503 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 25924 | 0.425 |
18 | 218210 | 0.420 |
7 | 148175 | 0.415 |
16 | 223356 | 0.410 |
13 | 554628 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 84662 | 8 |
0.435 | 131225 | 7 |
0.440 | 31424 | 6 |
0.445 | 27535 | 4 |
0.450 | 252495 | 3 |
Last trade - 12.58pm 29/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |